Compare Incyte Corporation (INCY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vale SA — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Vale SA trades at $14.13 (market cap $59.07B). The key difference: Vale SA is far larger — about 2.6× Incyte Corporation's market cap, and Vale SA pays a 8.93% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VALE | |
|---|---|---|
Market Cap | $23.11B | $59.07B |
Sector | Health | Basic Materials |
52-Week High | $118.52 | $17.82 |
52-Week Low | $67.38 | $9.53 |
Enterprise Value | $19.13B | $75.99B |
Dividend Yield | — | 8.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
VALE trades at $14.25, up 0.42% today but down 11% over the past month. Technical indicators show a bearish trend with moving averages signaling sell pressure. Fundamentally, revenue declined to $38.4B in 2025 with net income falling to $2.35B, though cash flow improved to $2.42B. Recent news highlights board governance disputes and a $2.6B decarbonization investment announced in June 2026.
The outlook remains cautious with mixed analyst ratings (40.5% buy, 48.7% hold) and a $17.13 consensus target. Risks include volatile iron ore prices and execution challenges, but stable cash flow and low debt provide some resilience. Upside depends on commodity demand recovery and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
